All In MedTech

FDA Clearance Tracker · P130021-S025

Medtronic CoreValve Evolut R XL system

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Oct 26, 2016 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Oct 26, 2016

Approved

Time to decision

13 days

Received Oct 13, 2016. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P130021-S025
Device name
Medtronic CoreValve Evolut R XL system
Applicant location
Miinneapolis, MN
Received
Oct 13, 2016
Decided
Oct 26, 2016
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P130021

Device type

Device class
Class III

Every decision under product code NPT

FDA's approval statement

As written in FDA's record.

Approval for a new size of the CoreValve Evolut R System. The new components include CoreValve Evolut R Transcatheter Aortic Valve, model EVOLUTR-34-US, EnVeo R Delivery Catheter System, model ENVEOR-N-US, and EnVeo™ R Loading System, model LS-ENVEOR-34-US.

Source documents

Other decisions for Medtronic, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.